Our colleague Matthew Herper joins us for a deep dive into Illumina, explaining how the biggest company in genome sequencing lost the faith of shareholders and painted itself into a corner. We’ll also discuss the latest news in the life sciences, including a look at what’s ahead in biotech for the second quarter of the year, and why Johnson & Johnson investors are happy the company is proposing to part with $9 billion.
The Readout Loud